TY - JOUR
T1 - Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone
AU - Goto, Naoe
AU - Tsurumi, Hisashi
AU - Takemura, Masao
AU - Kanemura, Nobuhiro
AU - Kasahara, Senji
AU - Hara, Takeshi
AU - Yasuda, Ichiro
AU - Shimizu, Masahito
AU - Yamada, Toshiki
AU - Sawada, Michio
AU - Takahashi, Takeshi
AU - Yamada, Tetsuya
AU - Seishima, Mitsuru
AU - Moriwaki, Hisataka
AU - Takami, Tsuyoshi
PY - 2012/8
Y1 - 2012/8
N2 - Since the introduction of rituximab (R), the prognosis for diffuse large B-cell lymphoma (DLBCL) has markedly improved. We evaluated the prognostic significance of serum soluble CD27 (sCD27) in 143 patients with DLBCL treated with cyclophosphamide, doxorubicin, vincristine and prednisolone plus rituximab (R-CHOP). Five-year overall survival rates for patients with sCD27≥213 U/mL or <213 U/mL were 38.7% and 76.8%, respectively (p = 0.0005). Multivariate analysis revealed that serum sCD27 was significantly correlated with OS (p = 0.047). Immunohistochemical staining for CD27 in lymphoma tissues revealed positive lymphoma cells in 22 cases (18.5%) and positive microenvironment T-cells in 62 cases (52.1%) and was negative in the remaining patients. In these three subgroups, median sCD27 levels were 336 U/mL, 242.6 U/mL and 109.9 U/mL, respectively (p = 0.004). Thus, serum sCD27 level is associated with CD27 expression on lymphoma cells, and may be a powerful prognostic factor for DLBCL.
AB - Since the introduction of rituximab (R), the prognosis for diffuse large B-cell lymphoma (DLBCL) has markedly improved. We evaluated the prognostic significance of serum soluble CD27 (sCD27) in 143 patients with DLBCL treated with cyclophosphamide, doxorubicin, vincristine and prednisolone plus rituximab (R-CHOP). Five-year overall survival rates for patients with sCD27≥213 U/mL or <213 U/mL were 38.7% and 76.8%, respectively (p = 0.0005). Multivariate analysis revealed that serum sCD27 was significantly correlated with OS (p = 0.047). Immunohistochemical staining for CD27 in lymphoma tissues revealed positive lymphoma cells in 22 cases (18.5%) and positive microenvironment T-cells in 62 cases (52.1%) and was negative in the remaining patients. In these three subgroups, median sCD27 levels were 336 U/mL, 242.6 U/mL and 109.9 U/mL, respectively (p = 0.004). Thus, serum sCD27 level is associated with CD27 expression on lymphoma cells, and may be a powerful prognostic factor for DLBCL.
UR - http://www.scopus.com/inward/record.url?scp=84864205412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864205412&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.660627
DO - 10.3109/10428194.2012.660627
M3 - Article
C2 - 22280534
AN - SCOPUS:84864205412
SN - 1042-8194
VL - 53
SP - 1494
EP - 1500
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 8
ER -